Highlights

  • License and collaboration revenue was $0.5 million for the second quarter of 2026, and the net loss was $122,678 thousand.
  • Cash, cash equivalents and marketable securities were $1.2 billion at June 30, 2026, funding at least 12 months, management said.
  • The company expects updated BEACON data and a risto-cel biologics license application as early as year-end 2026.
  • In February 2026, the company entered a Sixth Street Lending Partners financing agreement with an initial draw of $100.0 million.

Beam Therapeutics Inc. (NASDAQ:BEAM) shares were trading at USD 28.30 on October 28, 2026, up 13.65%, with a relative volume at time of 4.21. The gene editing company dosed the first patient in a BEAM-302 pivotal cohort in July 2026 and filed its quarterly report on Form 10-Q for the period ended June 30, 2026 on August 4, 2026.

Beam Therapeutics Inc. is incorporated in Delaware and lists its principal executive offices in Cambridge, Massachusetts. It describes itself as a biotechnology company building an integrated platform for precision genetic medicines, anchored by proprietary base editing technology, delivery technologies and internal manufacturing capabilities. Its programs include risto-cel for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-304 for phenylketonuria and BEAM-301 for glycogen storage disease type 1a. Its fiscal year ends December 31, and it had 420 research and development employees and 120 general and administrative employees at June 30, 2026.

Second Quarter 2026 Results

Beam reported license and collaboration revenue of $0.5 million for the three months ended June 30, 2026, compared with $8.5 million in the same period of 2025.

Research and development expenses were $95.1 million, compared with $101.8 million. General and administrative expenses were $31.9 million, compared with $26.9 million. Loss from operations was $126,553 thousand, compared with $120,151 thousand. Net loss was $122,678 thousand, compared with $102,138 thousand, and net loss per share was $1.18, compared with $1.00.

For the six months ended June 30, 2026, license and collaboration revenue was $32,228 thousand, compared with $15,936 thousand, and net loss was $216,996 thousand, compared with $210,468 thousand. The accumulated deficit was $1.9 billion at June 30, 2026.

Cash, Financing and Capital

Beam held cash, cash equivalents and marketable securities of $1.2 billion at June 30, 2026. The company said it expects this amount to fund operations for at least the next 12 months from the date the financial statements were issued, and that it will need additional financing to support continuing operations and pursue its growth strategy.

Net cash used in operating activities was $194,609 thousand for the six months, compared with $180,334 thousand. In February 2026, the company entered a financing agreement with lenders and Sixth Street Lending Partners. It provides for an initial draw of $100.0 million, up to $300 million available upon certain clinical, regulatory and commercial milestones for risto-cel, and an additional $100 million at the company's option, subject to mutual agreement. The facility matures on February 24, 2033.

Pipeline Developments

For risto-cel, the BEACON Phase 1/2 trial includes approximately 50 adults and adolescents with severe sickle cell disease, and dosing is complete for all adult and adolescent patients. Updated data were presented at the American Society of Hematology 2025 Annual Meeting and published in the New England Journal of Medicine on April 1, 2026. The filing reports that one patient died four months after infusion from respiratory failure that the investigator found likely related to busulfan conditioning and unrelated to risto-cel.

For BEAM-302, the company said that, based on FDA feedback, it intends to pursue an accelerated approval pathway based on an AAT biomarker endpoint evaluated over 12 months, with 60 mg as the selected dose. It anticipates enrolling approximately 50 additional patients in a pivotal expansion and dosed the first pivotal patient in July 2026.

Expected Milestones

The company said it expects to report updated BEACON data by year-end 2026 and to submit a biologics license application for risto-cel as early as year-end 2026. The filing does not give revenue or earnings guidance.